Simron Singh

Simron Singh, MD, MPH, FRCPC is Head of Medical Oncology at Sunnybrook Health Sciences Centre and Medical Director of the Susan Leslie Clinic for Neuroendocrine Tumours at the University of Toronto, the largest NET program in Canada. She is internationally recognized for her patient-centered research integrating health-related quality of life, patient-reported outcomes (PROs), and health services perspectives into NET clinical trials and clinical practice. Her work has demonstrated that carcinoid syndrome significantly impairs quality of life beyond diarrhea alone and has informed PRO endpoint design in pivotal NET trials including the TELECAST program. Dr. Singh has led prospective studies characterizing the lived experience of NET patients, including the impact of carcinoid syndrome on daily functioning, employment, and psychological wellbeing — areas largely invisible to traditional trial endpoints. She co-founded the Canadian NET Registry, a national prospective database enabling population-based studies of NET incidence, treatment patterns, and disparities in access across Canada's healthcare system. Her health equity research has revealed socioeconomic and geographic barriers to NET specialty care and novel therapies, motivating advocacy for improved access. A highly engaging educator and patient advocate, Dr. Singh is a past president of NANETS and a board member of the Carcinoid Cancer Foundation. She has published over 150 peer-reviewed articles and is a frequent voice for patients with NETs at international oncology meetings.